<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07072</article-id><article-id pub-id-type="doi">10.7554/eLife.07072</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-28457"><name><surname>Kandela</surname><given-names>Irawati</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-29159"><name><surname>Jin</surname><given-names>Hyun Yong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-29160"><name><surname>Owen</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Developmental Therapeutics Core</institution>, <institution>Northwestern University</institution>, <addr-line><named-content content-type="city">Evanston</named-content></addr-line>, <country>Illinois</country></aff><aff id="aff2"><label>2</label><institution>The Scripps Research Institute</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>California</country></aff><aff id="aff3"><label>3</label><institution>University of Virginia</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virgina</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-23497"><name><surname>Glass</surname><given-names>Christopher</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Diego</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange, Palo Alto</institution>, <addr-line><named-content content-type="city">California</named-content></addr-line></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virginia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>tim@cos.io</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>06</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e07072</elocation-id><history><date date-type="received"><day>17</day><month>02</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>06</month><year>2015</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name></person-group>. <year>2011</year>. <article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title>. <source>Cell</source> <volume>146</volume>:<fpage>904</fpage>–<lpage>917</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id>.</mixed-citation></p></fn></history><permissions><copyright-statement>© 2015, Kandela et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Kandela et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-07072-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.07072.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in <italic>Cell</italic> in 2011 (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; <xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; <xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published in <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.07072.001">http://dx.doi.org/10.7554/eLife.07072.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>methodology</kwd><kwd>bromodomain inhibitor</kwd><kwd>myeloma</kwd><kwd>targeted therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient>Reproducibility Project: Cancer Biology</principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.3</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>c-Myc is a DNA binding transcription factor involved in the regulation of cell proliferation, differentiation, and apoptosis (<xref ref-type="bibr" rid="bib22">McKeown and Bradner, 2014</xref>). Abnormal expression of c-Myc is frequently observed in a range of malignancies including breast, colon and cervical cancer, small cell lung carcinoma, osteosarcomas, glioblastomas and myeloid leukemias (<xref ref-type="bibr" rid="bib24">Meyer and Penn, 2008</xref>; <xref ref-type="bibr" rid="bib7">Conacci-Sorrell et al., 2014</xref>). While c-Myc expression is required for tumor initiation and maintenance, c-Myc inactivation leads to tumor regression (<xref ref-type="bibr" rid="bib12">Felsher and Bishop, 1999</xref>; <xref ref-type="bibr" rid="bib14">Flores et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Soucek et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Gabay et al., 2014</xref>). Therefore, c-Myc represents an enticing target for pharmacological inhibition.</p><p>Multiple myeloma (MM) is an incurable disease characterized by the unrestricted proliferation of terminally differentiated plasma cells (<xref ref-type="bibr" rid="bib2">Anderson et al., 2011</xref>). The primary tumor-initiating events include genetic translocation and hyperploidy, while secondary events, such as oncogenic c-Myc activation and overexpression, drive MM progression (<xref ref-type="bibr" rid="bib3">Bergsagel and Kuehl, 2005</xref>; <xref ref-type="bibr" rid="bib25">Morgan et al., 2012</xref>). Furthermore, studies by Chng and colleagues determined that c-Myc activation was prevalent in more than 60% of patient-derived MM cells (<xref ref-type="bibr" rid="bib5">Chng et al., 2011</xref>). Despite therapeutic advances and increases in survival, patients eventually succumb to treatment-refractory disease (<xref ref-type="bibr" rid="bib1">Anderson, 2011</xref>; <xref ref-type="bibr" rid="bib17">Kumar et al., 2012</xref>).</p><p>Therapeutic strategies targeting c-Myc are complicated by the fact that c-Myc lacks a clear ligand-binding domain (<xref ref-type="bibr" rid="bib8">Darnell, 2002</xref>). However, it is possible that c-Myc could be disrupted by other means, such as through disruption of chromatin-dependent signaling. Bromodomain and extraterminal (BET) proteins are transcriptional regulators that epigenetically control the expression of genes involved in cell cycle, growth and inflammation (<xref ref-type="bibr" rid="bib8">Darnell, 2002</xref>; <xref ref-type="bibr" rid="bib35">Wu and Chiang, 2007</xref>; <xref ref-type="bibr" rid="bib19">LeRoy et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Dey et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">Nicodeme et al., 2010</xref>). BETs therefore provide potential therapeutic targets for modulating gene expression programs associated with various human diseases. Specifically, bromodomain protein 4 (BRD4), a member of the BET subfamily that associates with acetylated chromatin to promote transcription, was reported to interact with the positive transcription elongation factor complex b (P-TEFb) (<xref ref-type="bibr" rid="bib10">Dey et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Filippakopoulos et al., 2010</xref>). Recruitment of P-TEFb by c-Myc was also reported, providing the rationale for Delmore and colleagues to explore targeting BET proteins to inhibit c-Myc transcriptional activity (<xref ref-type="bibr" rid="bib4">Bisgrove et al., 2007</xref>). Importantly, BRD4 expression was found to positively correlate with MM disease progression (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). To interrogate this relationship, they used JQ1, a small molecule inhibitor of the BET family of bromodomain-containing proteins, which has the highest affinity with BRD4 and competitively inhibits BET proteins from binding to chromatin (<xref ref-type="bibr" rid="bib13">Filippakopoulos et al., 2010</xref>). While the (+)-JQ1 enantiomer potently inhibits BET proteins, the (−)-JQ1 enantiomer is structurally incapable of inhibiting BET bromodomains supporting an on-target mechanism of action (<xref ref-type="bibr" rid="bib13">Filippakopoulos et al., 2010</xref>). Further support for the relationship between c-Myc and BET proteins was reported by Mertz and colleagues, who used gene expression profiling of cells treated with the active and inactive forms of the JQ1 inhibitor to identify <italic>MYC</italic> as a highly down-regulated gene following BET bromodomain inhibition (<xref ref-type="bibr" rid="bib23">Mertz et al., 2011</xref>).</p><p>As an alternative approach to direct c-Myc-targeting, Delmore and colleagues tested whether the BET inhibitor, JQ1, could effect c-Myc-specific gene silencing in MM (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). In Figure 3B, Delmore and colleagues assessed the ability of JQ1 to downregulate <italic>MYC</italic> transcription in the MM cell line MM.1S. In this experiment, MM.1S cells were treated with JQ1 for up to 8 hours and the relative expression of <italic>MYC</italic> was compared to untreated control cells. JQ1 treatment resulted in a significant reduction in <italic>MYC</italic> transcripts as determined by qRT-PCR. This key experiment shows that JQ1 was effective at silencing <italic>MYC</italic> gene transcription and will be replicated in Protocol 1. Importantly, Loven and colleagues also recently corroborated these results through the demonstration that JQ1 treatment in MM.1S cells significantly decreases <italic>MYC</italic> mRNA levels (<xref ref-type="bibr" rid="bib21">Loven et al., 2013</xref>). In addition to MM cell lines, JQ1 has proven to potently inhibit <italic>MYC</italic> in Merkel cell carcinoma cells (MCC-3 and 5), primary effusion lymphoma cells (PELs) and B cell acute lymphoblastic lymphomas (B-ALL) cells at the transcript level, as well as in diffuse large B cell lymphoma (DLBCL) cells at the protein expression level (<xref ref-type="bibr" rid="bib27">Ott et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Shao et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Tolani et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Trabucco et al., 2015</xref>). However, JQ1-resistant cells have also been described. Specifically, JQ1 did not alter <italic>MYC</italic> transcription in embryonic stem cells (ESCs) or in non-small cell lung carcinoma (NSCLC) harboring alteration in KRAS (<xref ref-type="bibr" rid="bib30">Shimamura et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Horne et al., 2014</xref>). In lung adenocarcinoma cells (LACs), JQ1 was found to inhibit cell growth independent of <italic>MYC</italic> down regulation (<xref ref-type="bibr" rid="bib20">Lockwood et al., 2012</xref>).</p><p>In Figure 7C, 7D and 7E, the efficacy of JQ1 treatment was tested in mice harboring bioluminescent MM lesions. In these experiments, tumor burden was measured by whole-body bioluminescent imaging. Delmore and colleagues showed that JQ1 treatment significantly decreased disease burden and increased survival time compared to vehicle-treated control animals (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>). Similar findings recapitulating the suppressive effect of JQ1 on solid tumor growth have been reported in MCC, DLBCL and PEL xenograft models (<xref ref-type="bibr" rid="bib27">Ott et al., 2012</xref>; <xref ref-type="bibr" rid="bib33">Tolani et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Trabucco et al., 2015</xref>), and reduced leukemic burden in a B-ALL xenograft model with corresponding improvements in survival (<xref ref-type="bibr" rid="bib27">Ott et al., 2012</xref>). These experiments will be replicated in Protocol 2.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Protocol 1: evaluation of <italic>MYC</italic> expression in JQ1-treated MM.1S cells</title><p>This experiment analyzes the expression of endogenous <italic>MYC</italic> during pharmacological inhibition of BET bromodomains with JQ1. This is a replication of the data presented in Figure 3B and assesses the levels of <italic>MYC</italic> by quantitative RT-PCR.</p><sec id="s2-1-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ Each experiment has 9 conditions:</p><list list-type="simple"><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 0 hr after (+)-JQ1 treatment.</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 1 hr after (+)-JQ1 treatment.</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 8 hr after (+)-JQ1 treatment.</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 0 hr after (−)-JQ1 treatment [additional].</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 1 hr after (−)-JQ1 treatment [additional].</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 8 hr after (−)-JQ1 treatment [additional].</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 0 hr after vehicle treatment [additional].</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 1 hr after vehicle treatment [additional].</p></list-item><list-item><p>◯ qRT-PCR of <italic>MYC</italic> (and <italic>GAPDH</italic>) 8 hr after vehicle treatment [additional].</p></list-item></list></list-item><list-item><p>■ Experiment will be performed five times with each run using three technical replicates, for a total power of ≥91%.</p><list list-type="simple"><list-item><p>◯ See ‘Power calculations’ section for details.</p></list-item></list></list-item></list></p></sec><sec id="s2-1-2"><title>Materials and reagents</title><p><table-wrap id="tbl1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MM.1S-LucNeo</td><td>Cell line</td><td>Original authors</td><td>N/A</td><td>Engineered to express luciferase</td></tr><tr><td>RPMI 1640 medium</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>R8758</td><td>With 2 mM L-glutamine. Original brand not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>F0392</td><td>Original brand not specified</td></tr><tr><td>100× Penicillin/streptomycin</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>P4333</td><td>Original brand not specified</td></tr><tr><td>PBS, without MgCl<sub>2</sub> and CaCl<sub>2</sub></td><td>Buffer</td><td>Sigma–Aldrich</td><td>D8537</td><td>Originally not specified</td></tr><tr><td>0.05% trypsin/0.48 mM EDTA</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>T3924</td><td>Originally not specified</td></tr><tr><td>35-mm tissue culture dishes</td><td>Labware</td><td>Corning</td><td>430165</td><td>Originally not specified</td></tr><tr><td>(+)-JQ1 enantiomer</td><td>Chemical</td><td rowspan="2">EMD Millipore</td><td rowspan="2">500586</td><td rowspan="2">Original made by authors</td></tr><tr><td>(−)-JQ1 enantiomer</td><td>Chemical</td></tr><tr><td>DMSO</td><td>Chemical</td><td>Sigma–Aldrich</td><td>D8418</td><td>Original brand not specified</td></tr><tr><td>TRI reagent</td><td>Chemical</td><td>Sigma–Aldrich</td><td>T9424</td><td>Replaces TRIzol from Invitrogen (Cat #15596-026)</td></tr><tr><td>First-Strand cDNA Synthesis kit</td><td>Nucleic acid</td><td>GE Healthcare (Sigma–Aldrich)</td><td>GE27-9261-01</td><td>–</td></tr><tr><td>Real-time PCR system</td><td>Instrument</td><td>Applied Biosystems</td><td>7900HT</td><td>Replaces 7500 model</td></tr><tr><td>TaqMan Gene Expression Master Mix</td><td>Nucleic acid</td><td>Life Technologies</td><td>4369016</td><td>Replaces a real-time PCR kit from Applied Biosystems (Cat #N15597), which is discontinued</td></tr><tr><td>Taq-Man probe (<italic>MYC</italic>)</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Hs00905030_m1</td><td>–</td></tr><tr><td>Taq-Man probe (<italic>Gapdh</italic>)</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Hs02758991_g1</td><td>–</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-1-3"><title>Procedure</title><sec id="s2-1-3-1"><title>Notes</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling.</p></list-item><list-item><p>Cells maintained in RPMI 1640 with 2 mM L-glutamine supplemented with 10% FBS, 100 U/ml penicillin, and 50 µg/ml streptomycin at 37°C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item></list><list list-type="order"><list-item><p>Seed 8 × 10<sup>5</sup> MM.1S-LucNeo cells into three 35-mm tissue culture dishes.</p></list-item><list-item><p>The next day treat the dishes of cells with 2 ml of media with a final concentration of 500 nM (+)-JQ1, 500 nM (−)-JQ1, or an equivalent volume of DMSO.</p><list list-type="simple"><list-item><p>a. Make 10 mM stock of (+)-JQ1 and (−)-JQ1 by diluting in DMSO.</p></list-item></list></list-item><list-item><p>Isolate RNA from dishes at the following time points after treatment using TRI Reagent following manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. 0 hr (immediately).</p></list-item><list-item><p>b. 1 hr.</p></list-item><list-item><p>c. 8 hr.</p></list-item></list></list-item><list-item><p>Reverse transcribe total RNA to cDNA with reverse transcription kit following manufacturer's instructions.</p><list list-type="simple"><list-item><p>a. Record RNA concentration and purity.</p></list-item><list-item><p>b. Use 1 µg of RNA per 50 µl reaction.</p></list-item><list-item><p>c. Use random hexamers for first-strand synthesis.</p></list-item></list></list-item><list-item><p>Perform qPCR to assess <italic>MYC</italic> expression levels using a real-time PCR system with a real-time PCR kit following manufacturer's instructions. Perform triplicate technical replicates for each biological replicate.</p><list list-type="simple"><list-item><p>a. Use 5 µl of undiluted cDNA mixture per 50 µl reaction.</p></list-item><list-item><p>b. Use TaqMan probes for <italic>MYC</italic> (Hs00905030_m1) and <italic>Gapdh</italic> (Hs02758991_g1).</p></list-item></list></list-item><list-item><p>Analyze and compute ΔΔC<sub>T</sub> values.</p><list list-type="simple"><list-item><p>a. The first qRT-PCR assay will be analyzed to ensure conditions are appropriate for proper quantitation. If it is determined that conditions need to be adjusted, such as input volume, the conditions will be adjusted and the reaction will be repeated. Once optimized, the conditions will be used for all subsequent reactions.</p><list list-type="simple"><list-item><p>i. All details and data associated with this process will be recorded.</p></list-item></list></list-item></list></list-item><list-item><p>Repeat steps 1–6 independently four additional times.</p></list-item></list></p></sec><sec id="s2-1-3-2"><title>Deliverables</title><p><list list-type="simple"><list-item><p>■ Data to be collected:</p><list list-type="simple"><list-item><p>◯ Purity (A<sub>260/280</sub> ratio) and concentration of isolated total RNA from cells.</p></list-item><list-item><p>◯ Assay conditions used initially and, if necessary, modified, to ensure conditions are appropriate for proper quantitation.</p></list-item><list-item><p>◯ Raw qRT-PCR values, as well as analyzed ΔΔC<sub>T</sub> values.</p></list-item><list-item><p>◯ Bar graph of <italic>MYC</italic> mRNA levels normalized to 0 hr after (+)-JQ1 treatment. (Compare to Figure 3B).</p></list-item></list></list-item></list></p></sec></sec><sec id="s2-1-4"><title>Confirmatory analysis plan</title><p>This replication attempt will perform the following statistical analysis listed below.<list list-type="simple"><list-item><p>■ Statistical analysis:</p><list list-type="simple"><list-item><p>◯ Repeated measures ANOVA of normalized <italic>MYC</italic> mRNA levels in MM.1S cells treated with (+)-JQ1, (−)-JQ1, or DMSO.</p><list list-type="bullet"><list-item><p>Paired <italic>t</italic>-tests with the Bonferroni correction:</p><list list-type="order"><list-item><p>MM.1S cells harvested 8 hr after (+)-JQ1 treatment compared to cells 0 hr after (+)-JQ1 treatment.</p></list-item><list-item><p>MM.1S cells harvested 1 hr after (+)-JQ1 treatment compared to cells 0 hr after (+)-JQ1 treatment.</p></list-item></list></list-item></list></list-item></list></list-item><list-item><p>■ Additional exploratory statistical Analysis:</p><list list-type="simple"><list-item><p>◯ Two-way ANOVA of normalized <italic>MYC</italic> mRNA levels in MM.1S cells treated with (+)-JQ1, (−)-JQ1, or DMSO.</p><list list-type="bullet"><list-item><p>Planned comparisons with the Bonferroni correction:</p><list list-type="order"><list-item><p>MM.1S cells harvested 8 hr after (+)-JQ1 treatment compared to cells 0 hr after (+)-JQ1 treatment.</p></list-item><list-item><p>MM.1S cells harvested 1 hr after (+)-JQ1 treatment compared to cells 0 hr after (+)-JQ1 treatment.</p></list-item></list></list-item></list></list-item></list></list-item><list-item><p>■ Meta-analysis of effect sizes:</p><list list-type="simple"><list-item><p>◯ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></list-item></list></p></sec><sec id="s2-1-5"><title>Known differences from the original study</title><p>The replication experiment will not include the full time course treatment with (+)-JQ1, but will only include the 0 hr, 1 hr, and 8 hr treatments. The replication experiment will also include six additional conditions; MM.1S cells harvested 0 hr, 1 hr, and 8 hr after treatment with (−)-JQ1 or DMSO. The original report was unclear if the cells used for this experiment were MM.1S or MM.1S-LucNeo cells. This replication attempt will use MM.1S-LucNeo cells since this is the same cell line used in protocol 2 to assess the efficacy of JQ1 treatment in mice. The original details for the reverse transcription and qRT-PCR reactions were not known, thus the details used here are manufacturer recommended with the use of random hexamers to generate cDNA that are more representative of all regions of the transcripts. Following the first reaction, conditions will be adjusted if necessary to ensure proper quantitation. All known differences of materials and reagents are listed in the ‛Materials and reagents’ section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-1-6"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. The sample purity (A<sub>260/280</sub> and A<sub>260/230</sub> ratios) of the isolated RNA from each sample will be reported. The first qRT-PCR reaction will be analyzed to determine if the assay conditions are appropriate for proper quantitation. This would be apparent after the first qRT-PCR assay, and the assay would then be repeated adjusting parameters. After conditions that allow for proper quantitation are achieved, then the number of pre-determined replicates will be completed under those same conditions. All assay details, adjustments, and data will be recorded and made available during this optimization process. All data obtained from the experiment—raw data, data analysis, control data, and quality control data—will be made publicly available, either in the published manuscript or as an open access data set available on the Open Science Framework project page for this study (<ext-link ext-link-type="uri" xlink:href="https://osf.io/7zqxp/">https://osf.io/7zqxp/</ext-link>).</p></sec></sec><sec id="s2-2"><title>Protocol 2: JQ1 treatment in orthotopic xenograft model</title><p>This experiment tests the efficacy of JQ1 treatment in mice harboring bioluminescent MM lesions. This is a replication of the data presented in Figures 7C, 7D, and 7E and assesses tumor burden by whole-body bioluminescent imaging and monitors overall survival with daily treatment of JQ1.</p><sec id="s2-2-1"><title>Sampling</title><p><list list-type="simple"><list-item><p>■ Each experiment has 3 cohorts:</p><list list-type="simple"><list-item><p>◯ Cohort 1: Vehicle (D5W) treatment.</p></list-item><list-item><p>◯ Cohort 2: (+)-JQ1 treatment.</p></list-item><list-item><p>◯ Cohort 3: (−)-JQ1 treatment [additional].</p></list-item></list></list-item><list-item><p>■ Experiment will analyze at least eight mice per cohort for a minimum of 80% power.</p><list list-type="simple"><list-item><p>◯ See ‘Power calculations’ section for details.</p></list-item></list></list-item><list-item><p>■ To account for unexpected euthanasia of mice before the end of the experiment or exclusion of mice before treatment, the sample size was increased by ∼ 30%.</p><list list-type="simple"><list-item><p>◯ A total of 33 mice will be injected with MM.1S-LucNeo cells.</p></list-item></list></list-item></list></p></sec><sec id="s2-2-2"><title>Materials and reagents</title><p><table-wrap id="tbl2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>MM.1S-LucNeo</td><td>Cell line</td><td>Original authors</td><td>N/A</td><td>Engineered to express luciferase</td></tr><tr><td>RPMI 1640 medium</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>R8758</td><td>With 2 mM L-glutamine. Original brand not specified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>F0392</td><td>Original brand not specified</td></tr><tr><td>100× penicillin/streptomycin</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>P4333</td><td>Original brand not specified</td></tr><tr><td>PBS, without MgCl<sub>2</sub> and CaCl<sub>2</sub></td><td>Buffer</td><td>Sigma–Aldrich</td><td>D8537</td><td>Originally not specified</td></tr><tr><td>0.05% trypsin/0.48 mM EDTA</td><td>Cell culture</td><td>Sigma–Aldrich</td><td>T3924</td><td>Originally not specified</td></tr><tr><td>T150 tissue culture flasks</td><td>Labware</td><td>Corning</td><td>430825</td><td>Originally not specified</td></tr><tr><td>5 week old female Fox Chase SCID Beige (CB17.Cg-<italic>Prkdc</italic><sup><italic>scid</italic></sup><italic>Lyst</italic><sup><italic>bg-J</italic></sup>/Crl)</td><td>Animal model</td><td>Charles River Labs</td><td>Strain 250</td><td>–</td></tr><tr><td>30½G needle</td><td>Labware</td><td>Sigma–Aldrich</td><td>Z192341</td><td>Originally not specified</td></tr><tr><td>27½G needle</td><td>Labware</td><td>Sigma–Aldrich</td><td>Z192384</td><td>Originally not specified</td></tr><tr><td>1 ml syringe</td><td>Labware</td><td>Sigma–Aldrich</td><td>Z192090</td><td>Originally not specified</td></tr><tr><td>VivoGlo luciferin</td><td>Reporter assay</td><td>Promega</td><td>P1042</td><td>Original catalog # not specified</td></tr><tr><td>Xenogen IVIS Spectrum</td><td>Instrument</td><td>Caliper Life Sciences</td><td>Spectrum</td><td>–</td></tr><tr><td>Living Images</td><td>Software</td><td>Caliper Life Sciences</td><td colspan="2">Version used will be recorded and included in the Replication Study</td></tr><tr><td>(+)-JQ1 enantiomer</td><td>Chemical</td><td rowspan="2">EMD Millipore</td><td rowspan="2">500586</td><td rowspan="2">Original made by authors</td></tr><tr><td>(−)-JQ1 enantiomer</td><td>Chemical</td></tr><tr><td>Dextrose (D-(+)-glucose)</td><td>Chemical</td><td>Sigma–Aldrich</td><td>G8270</td><td>Original brand not specified</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-2-3"><title>Procedure</title><sec id="s2-2-3-1"><title>Notes</title><p><list list-type="bullet"><list-item><p>All cells will be sent for mycoplasma testing and STR profiling, as well as screened against a Rodent Pathogen Panel.</p></list-item><list-item><p>Cells maintained in RPMI 1640 with 2 mM L-glutamine supplemented with 10% FBS, 100 U/ml penicillin, and 50 µg/ml streptomycin at 37°C in a humidified atmosphere at 5% CO<sub>2</sub>.</p></list-item><list-item><p>MM.1S-LucNeo cells stably express a luciferase construct.</p></list-item></list><list list-type="order"><list-item><p>After 1 week of acclimation, intravenously inject 2 × 10<sup>6</sup> MM.1S-LucNeo cells suspended in 200 µl PBS into 6-week old female SCID-beige mice using a 30½G needle via the lateral tail vein.</p></list-item><list-item><p>8 days later, inject mice intraperitoneally with 75 mg/kg of D-luciferin in 0.1 ml using a 27½G needle. Anesthetize mice and image using a Xenogen IVIS Spectrum using the Living Images software package.</p><list list-type="simple"><list-item><p>a. Record weight of mice.</p></list-item><list-item><p>b. Anesthetize with isoflurane.</p></list-item><list-item><p>c. Image mice 20 min post injection.</p></list-item></list></list-item><list-item><p>5 days later, inject mice with 75 mg/kg of D-luciferin as described in step 2 and image using a Xenogen IVIS Spectrum using the Living Images software package.</p><list list-type="simple"><list-item><p>a. Record weight of mice.</p></list-item><list-item><p>b. Determine difference between bioluminescence of first imaging and second imaging.</p></list-item></list></list-item><list-item><p>For mice with established disease, randomly divide into three cohorts.</p><list list-type="simple"><list-item><p>a. Established disease is defined as detection of MM.1S-LucNeo lesions diffusely engrafted in the skeleton with an increase in bioluminescence between the first and second images.</p></list-item><list-item><p>b. Exclude any mice with no detectable disease or no increase in bioluminescence. If over 30 mice are present with detectable disease, exclude mice with lowest disease burden to obtain 30 mice for randomization and treatment.</p><list list-type="simple"><list-item><p>i. Original report saw 90–95% engraftment.</p></list-item></list></list-item><list-item><p>c. Animals are ranked according to disease burden (difference between bioluminescence of first imaging and second imaging), to balance groups for baseline tumor characteristics, and assigned to group 1, group 2, or group 3 using an alternating serpentine method. (rank 1 = group 1, rank 2 = group 2, rank 3 = group 3, rank 4 = group 3, rank 5 = group 2, rank 6 = group 1, rank 7 = group 1, etc).</p><list list-type="simple"><list-item><p>i. Designation of Vehicle, (+)-JQ1, or (−)-JQ1 treatments as group 1, group 2, or group 3 will be determined by randomly assigning the three treatments into one block using <ext-link ext-link-type="uri" xlink:href="http://www.randomization.com/">www.randomization.com</ext-link>.</p></list-item><list-item><p>ii. Record seed number.</p></list-item></list></list-item></list></list-item><list-item><p>After imaging and randomization, treat mice daily with either (+)-JQ1 at 50 mg/kg, (−)-JQ1 at 50 mg/kg, or vehicle (5% dextrose in water) control by intraperitoneal injection with a 27½G needle.</p><list list-type="simple"><list-item><p>a. Inject 10 ml/kg body weight of a 5 mg/ml solution to give a final dose of 50 mg/kg.</p><list list-type="simple"><list-item><p>i. (+)-JQ1 and (−)-JQ1 solutions are prepared in 5% dextrose in water.</p></list-item></list></list-item><list-item><p>b. Record weight of mice.</p></list-item></list></list-item><list-item><p>6, 14, and 21 days after the start of treatment IP injections, assess tumor burden by bioluminescence imaging after IP injection of 75 mg/kg of D-luciferin as described in step 2 above.</p><list list-type="simple"><list-item><p>a. Record weight of mice.</p></list-item></list></list-item><list-item><p>Continue to treat mice with daily injections of (+)-JQ1, (−)-JQ1, or vehicle control until mice are euthanized according to IACUC guidelines or until end of experiment (5 weeks total treatment).</p><list list-type="simple"><list-item><p>a. In this model, mice are euthanized when they develop hind limb paralysis.</p></list-item></list></list-item></list></p></sec><sec id="s2-2-3-2"><title>Deliverables</title><p><list list-type="simple"><list-item><p>■ Data to be collected:</p><list list-type="simple"><list-item><p>◯ Mouse health records (including number of mice with established disease and reason for euthanasia, weight at time of each injection).</p></list-item><list-item><p>◯ All images of mice in vivo to detect established disease and tumor burden (compare to Figure 7C).</p></list-item><list-item><p>◯ Raw photon flux measurements of each mouse and graph of bioluminescence vs day of treatment of cohorts (compare to Figure 7D).</p></list-item><list-item><p>◯ Raw survival data and Kaplan–Meier curves generated for percent survival (compare to Figure 7E).</p></list-item></list></list-item></list></p></sec></sec><sec id="s2-2-4"><title>Confirmatory analysis plan</title><p>This replication attempt will perform the following statistical analyses listed below.<list list-type="simple"><list-item><p>■ Statistical analysis:</p><list list-type="simple"><list-item><p>◯ Tumor burden:</p><list list-type="bullet"><list-item><p>One-way ANOVA test on day 22 data points with the following planned comparisons using Fisher's LSD correction:</p><list list-type="simple"><list-item><p>i. (+)-JQ1 treatment to vehicle treatment.</p></list-item><list-item><p>ii. (+)-JQ1 treatment to (−)-JQ1 treatment.</p></list-item></list></list-item><list-item><p>One-way ANCOVA test of the area under the curve (AUC) measurements (determined from day 1, 7, 15, and 22 data for each mouse) with the AUC pre-treatment measurements (determined from day −4 and 1 for each mouse) as the covariate, with the following planned comparisons with the Bonferroni correction:</p><list list-type="simple"><list-item><p>i. (+)-JQ1 treatment to vehicle treatment.</p></list-item><list-item><p>ii. (+)-JQ1 treatment to (−)-JQ1 treatment.</p></list-item><list-item><p>Note: This is an additional test not originally performed, which analyzes all data points opposed to just day 22 data points.</p></list-item></list></list-item></list></list-item><list-item><p>◯ Kaplan–Meier curves:</p><list list-type="bullet"><list-item><p>Log-rank Mantel–Cox test on the following comparisons with the Bonferroni correction:</p><list list-type="simple"><list-item><p>i. (+)-JQ1 treatment to vehicle treatment.</p></list-item><list-item><p>ii. (+)-JQ1 treatment to (−)-JQ1 treatment.</p></list-item></list></list-item></list></list-item></list></list-item><list-item><p>■ Meta-analysis of effect sizes:</p><list list-type="simple"><list-item><p>◯ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></list-item></list></p></sec><sec id="s2-2-5"><title>Known differences from the original study</title><p>The replication experiment will include an additional cohort receiving treatment with the inactive (−)-JQ1 enantiomer, which was not included in the original study. All known differences of materials and reagents are listed in the ‘Materials and reagents’ section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></sec><sec id="s2-2-6"><title>Provisions for quality control</title><p>The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Additionally, cells used for xenograft injection will be screened against a Rodent Pathogen Panel to ensure no contamination prior to injection. The bioluminescence images and measurements will be reported for all mice when determining the inclusion based on detection of lesions diffusely engrafted in the skeleton. Mice will be randomly assigned to treatment group with disease burden balanced among groups with the seed number recorded to reproduce the plan. All data obtained from the experiment—raw data, data analysis, control data, and quality control data—will be made publicly available, either in the published manuscript or as an open access data set available on the Open Science Framework project page for this study (<ext-link ext-link-type="uri" xlink:href="https://osf.io/7zqxp/">https://osf.io/7zqxp/</ext-link>).</p></sec></sec></sec><sec id="s3"><title>Power calculations</title><p>For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:<list list-type="simple"><list-item><p>■ <ext-link ext-link-type="uri" xlink:href="https://osf.io/bjrpc/">https://osf.io/bjrpc/</ext-link>.</p></list-item></list></p><sec id="s3-1"><title>Protocol 1</title><p>Summary of original data presented in Figure 3B (estimated from graph).<table-wrap id="tbl3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset being analyzed</th><th>N</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>MM.1S cells treated with (+)-JQ1–0 hr</td><td>2<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>1.0</td><td>0.375</td></tr><tr><td>MM.1S cells treated with (+)-JQ1–1 hr</td><td>2<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>0.06875</td><td>0.00625</td></tr><tr><td>MM.1S cells treated with (+)-JQ1–8 hr</td><td>2<xref ref-type="table-fn" rid="tblfn1">*</xref></td><td>0.0875</td><td>0.05</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>This is the number of biological replicates reported for this experiment.</p></fn></table-wrap-foot></table-wrap></p><p>We are including the following groups in the replication study: (−)-JQ1 and vehicle treatment. We performed these calculations with the assumption that (−)-JQ1–0 hr, 1 hr, and 8 hr, and vehicle–0 hr, 1 hr, and 8 hr will have similar values as (+)-JQ1–0 hr.</p><sec id="s3-1-1"><title>Analysis with samples paired</title><sec id="s3-1-1-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ ANOVA: Repeated measures, within factors, alpha error = 0.05.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p><list list-type="simple"><list-item><p>◯ The correlation among repeated measures was assumed to be 0 and the nonsphericity correction was assumed to be 1.</p></list-item></list></list-item></list></list-item></list><table-wrap id="tbl4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Groups</th><th>Detectable effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>0 hr, 1 hr, and 8 hr</td><td>(+)-JQ1, (−)-JQ1<xref ref-type="table-fn" rid="tblfn2">*</xref>, vehicle<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>0.41611<xref ref-type="table-fn" rid="tblfn3">†</xref></td><td>80.0%<xref ref-type="table-fn" rid="tblfn3">†</xref></td><td>15<xref ref-type="table-fn" rid="tblfn4">‡</xref> (3 groups, 3 measurments)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>*</label><p>(−)-JQ1 and vehicle values were the same as (+)-JQ1–0 hr values for this calculation.</p></fn><fn id="tblfn3"><label>†</label><p>This is the effect size detectable with 80% power and the indicated sample size.</p></fn><fn id="tblfn4"><label>‡</label><p>A total sample size of 15 will be used based on the paired <italic>t</italic>-test planned comparison calculations.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-1-1-2"><title>Test family</title><p><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two dependent means (matched pairs): Bonferroni's correction: alpha error = 0.025.</p><list list-type="simple"><list-item><p>■ Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p><list list-type="simple"><list-item><p>◯ Correlation between groups was assumed to be 0.</p></list-item></list></list-item></list></list-item></list><table-wrap id="tbl5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic><sub><italic>z</italic></sub></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>(+)-JQ1–0 hr</td><td>(+)-JQ1–8 hr</td><td>2.41199</td><td>90.8%</td><td>5</td></tr><tr><td>(+)-JQ1–0 hr</td><td>(+)-JQ1–1 hr</td><td>2.48299</td><td>92.3%</td><td>5</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s3-1-2"><title>Analysis with samples unpaired</title><sec id="s3-1-2-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Two-way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANOVA F statistic calculated with R software 3.1.2 (<xref ref-type="bibr" rid="bib32">Team RC, 2014</xref>).</p></list-item><list-item><p>F test statistic (interaction) calculated from <xref ref-type="bibr" rid="bib6">Cohen (2002)</xref>.</p></list-item><list-item><p>Partial η<sup>2</sup> calculated from <xref ref-type="bibr" rid="bib18">Lakens (2013)</xref>.</p></list-item></list></list-item></list><table-wrap id="tbl6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Groups</th><th>F test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>0 hr, 1 hr, and 8 hr</td><td>(+)-JQ1, (−)-JQ1<xref ref-type="table-fn" rid="tblfn5">*</xref>, vehicle<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>F(4,9) = 1.7228 (interaction)</td><td>0.4336</td><td>0.87503</td><td>82.4%<xref ref-type="table-fn" rid="tblfn6">†</xref></td><td>23<xref ref-type="table-fn" rid="tblfn6">†</xref> (9 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>*</label><p>(−)-JQ1 and vehicle values were the same as (+)-JQ1–0 hr values for this calculation.</p></fn><fn id="tblfn6"><label>†</label><p>A total sample size of 45 will be used based on the paired <italic>t</italic>-test planned comparison calculations making the power 99.7%.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-1-2-2"><title>Test family</title><p><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means: Bonferroni's correction: alpha error = 0.025.</p></list-item></list></p><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).<table-wrap id="tbl7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>(+)-JQ1–0 hr</td><td>(+)-JQ1–8 hr</td><td>3.41107</td><td>93.3%<xref ref-type="table-fn" rid="tblfn7">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn7">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn7">*</xref></td></tr><tr><td>(+)-JQ1–0 hr</td><td>(+)-JQ1–1 hr</td><td>3.51148</td><td>95.5%<xref ref-type="table-fn" rid="tblfn8">†</xref></td><td>4<xref ref-type="table-fn" rid="tblfn8">†</xref></td><td>4<xref ref-type="table-fn" rid="tblfn8">†</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><label>*</label><p>5 per group will be used based on the paired <italic>t</italic>-test planned comparisons making the power 98.7%.</p></fn><fn id="tblfn8"><label>†</label><p>5 per group will be used based on the paired <italic>t</italic>-test planned comparisons making the power 99.1%.</p></fn></table-wrap-foot></table-wrap></p></sec></sec></sec><sec id="s3-2"><title>Protocol 2</title><sec id="s3-2-1"><title>Tumor burden as determined by bioluminescence</title><p>Summary of original data presented in Figure 7D (provided by authors).<table-wrap id="tbl8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset being analyzed</th><th>Day</th><th>N</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td rowspan="5">Vehicle-treated mice</td><td>−4</td><td>10</td><td>2.14 × 10<sup>6</sup></td><td>9.38 × 10<sup>5</sup></td></tr><tr><td>1</td><td>10</td><td>1.06 × 10<sup>7</sup></td><td>7.63 × 10<sup>6</sup></td></tr><tr><td>7</td><td>10</td><td>2.37 × 10<sup>8</sup></td><td>7.98 × 10<sup>7</sup></td></tr><tr><td>15</td><td>10</td><td>6.40 × 10<sup>9</sup></td><td>3.13 × 10<sup>9</sup></td></tr><tr><td>22</td><td>10</td><td>1.85 × 10<sup>10</sup></td><td>1.01 × 10<sup>10</sup></td></tr><tr><td rowspan="5">(+)-JQ1-treated mice</td><td>−4</td><td>9</td><td>1.59 × 10<sup>6</sup></td><td>2.84 × 10<sup>5</sup></td></tr><tr><td>1</td><td>9</td><td>8.10 × 10<sup>6</sup></td><td>3.31 × 10<sup>6</sup></td></tr><tr><td>7</td><td>9</td><td>5.78 × 10<sup>7</sup></td><td>2.84 × 10<sup>7</sup></td></tr><tr><td>15</td><td>9</td><td>1.10 × 10<sup>9</sup></td><td>5.70 × 10<sup>8</sup></td></tr><tr><td>22</td><td>9</td><td>5.52 × 10<sup>9</sup></td><td>2.25 × 10<sup>9</sup></td></tr></tbody></table></table-wrap></p><p>Area under the curve (AUC) calculations from estimated values from graph in Figure 7D.</p><p>Calculations performed with R software 3.1.2 (<xref ref-type="bibr" rid="bib32">Team RC, 2014</xref>).<table-wrap id="tbl9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Data set being analyzed</th><th>Days</th><th>N</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td rowspan="2">Vehicle-treated mice</td><td>−4 to 1</td><td>10</td><td>3.02 × 10<sup>7</sup></td><td>2.30 × 10<sup>7</sup></td></tr><tr><td>1 to 22</td><td>10</td><td>1.14 × 10<sup>11</sup></td><td>5.08 × 10<sup>10</sup></td></tr><tr><td rowspan="2">(+)-JQ1-treated mice</td><td>−4 to 1</td><td>10</td><td>2.51 × 10<sup>7</sup></td><td>9.46 × 10<sup>6</sup></td></tr><tr><td>1 to 22</td><td>10</td><td>2.80 × 10<sup>10</sup></td><td>8.72 × 10<sup>9</sup></td></tr></tbody></table></table-wrap></p><p>We are including the following group in the replication study: (−)-JQ1-treated mice. We performed these calculations with the assumption that (−)-JQ1-treated mice will have similar values as vehicle-treated mice.</p></sec><sec id="s3-2-2"><title>Day 22 values</title><sec id="s3-2-2-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ F test: ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANOVA F test statistic calculated with R software 3.1.2 (<xref ref-type="bibr" rid="bib32">Team RC, 2014</xref>).</p></list-item><list-item><p>F test statistic (interaction) calculated from <xref ref-type="bibr" rid="bib6">Cohen (2002)</xref>.</p></list-item><list-item><p>Partial η<sup>2</sup> calculated from <xref ref-type="bibr" rid="bib18">Lakens (2013)</xref>.</p></list-item></list></list-item></list><table-wrap id="tbl10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Data</th><th>F test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>(+)-JQ1, (−)-JQ1<xref ref-type="table-fn" rid="tblfn10">*</xref>, vehicle</td><td>22 days</td><td>F(2,26) = 7.2114</td><td>0.35680</td><td>0.74480</td><td>80.8%<xref ref-type="table-fn" rid="tblfn11">†</xref></td><td>21<xref ref-type="table-fn" rid="tblfn11">†</xref> (3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn10"><label>*</label><p>(−)-JQ1 values were the same as vehicle values for this calculation.</p></fn><fn id="tblfn11"><label>†</label><p>8 per group (24 total) will be used based on the planned comparisons making the power 86.8%.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-2-2-2"><title>Test family</title><p><list list-type="simple"><list-item><p>■ 2 tailed <italic>t</italic> test: Means: Difference between two independent means: Fisher's LSD correction: alpha error = 0.05.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p></list-item></list></list-item></list><table-wrap id="tbl11" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>(+)-JQ1</td><td>Vehicle</td><td>1.52437</td><td>80.9%</td><td>8</td><td>8</td></tr><tr><td>(+)-JQ1</td><td>(−)-JQ1</td><td>1.52437</td><td>80.9%</td><td>8</td><td>8</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s3-2-3"><title>AUC values</title><sec id="s3-2-3-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ F test: ANCOVA: Fixed effects, main effects and interactions, alpha error = 0.05.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANCOVA F test statistic calculated with R software 3.1.2 (<xref ref-type="bibr" rid="bib32">Team RC, 2014</xref>).</p></list-item><list-item><p>Partial η<sup>2</sup> calculated from <xref ref-type="bibr" rid="bib18">Lakens (2013)</xref>.</p></list-item></list></list-item></list><table-wrap id="tbl12" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Data</th><th>F test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>(+)-JQ1, (−)-JQ1<xref ref-type="table-fn" rid="tblfn12">*</xref>, vehicle</td><td>AUC<xref ref-type="table-fn" rid="tblfn13">†</xref></td><td>F(2,25) = 36.051</td><td>0.74254</td><td>1.69826</td><td>98.3%<xref ref-type="table-fn" rid="tblfn14">‡</xref></td><td>11<xref ref-type="table-fn" rid="tblfn14">‡</xref> (3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn12"><label>*</label><p>(−)-JQ1 values were the same as vehicle values for this calculation.</p></fn><fn id="tblfn13"><label>†</label><p>One covariate was used (days −4 to 1 AUC) for this calculation.</p></fn><fn id="tblfn14"><label>‡</label><p>8 per group (24 total) will be used based on the day 22 calculations making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3-2-3-2"><title>Test family</title><p><list list-type="simple"><list-item><p>■ 2 tailed <italic>t</italic> test: Means: Difference between two independent means: Bonferroni correction: alpha error = 0.025.</p><list list-type="bullet"><list-item><p>Power calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib11">Faul et al., 2007</xref>).</p></list-item></list></list-item></list><table-wrap id="tbl13" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 1 adjusted mean</th><th>Group 2</th><th>Group 2 adjusted mean</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>(+)-JQ1</td><td>1.12 × 10<sup>11</sup></td><td>Vehicle</td><td>3.45 × 10<sup>10</sup></td><td>3.43522</td><td>93.6%<xref ref-type="table-fn" rid="tblfn15">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn15">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn15">*</xref></td></tr><tr><td>(+)-JQ1</td><td>1.12 × 10<sup>11</sup></td><td>(−)-JQ1</td><td>3.45 × 10<sup>10</sup></td><td>3.43522</td><td>93.6%<xref ref-type="table-fn" rid="tblfn15">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn15">*</xref></td><td>4<xref ref-type="table-fn" rid="tblfn15">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn15"><label>*</label><p>8 per group will be used based on the day 22 calculations making the power 99.9%.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s3-2-4"><title>Survival data</title><p>Summary of original data presented in Figure 7E (provided by authors).<table-wrap id="tbl14" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Dataset being analyzed</th><th>Median survival</th><th>Hazard ratio (to vehicle control)</th><th>N</th></tr></thead><tbody><tr><td>Vehicle-treated mice</td><td>22 days</td><td>NA</td><td>10</td></tr><tr><td>JQ1-treated mice</td><td>35 days</td><td>0.038565</td><td>9<xref ref-type="table-fn" rid="tblfn16">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn16"><label>*</label><p>Only 9 animals were analyzed in this group.</p></fn></table-wrap-foot></table-wrap></p><p>We are including the following comparisons in the replication study: (+)-JQ1-treated mice to (−)-JQ1-treated mice. We performed these calculations with the assumption that (−)-JQ1-treated mice will have similar values as vehicle-treated mice.</p><sec id="s3-2-4-1"><title>Test family</title><p><list list-type="simple"><list-item><p>■ Log-rank (Mantel–Cox) test: Bonferroni correction: alpha error = 0.025.</p><list list-type="bullet"><list-item><p>Power calculations performed with the <ext-link ext-link-type="uri" xlink:href="http://www.sample-size.net/sample-size-survival-analysis/">Sample Size Calculator</ext-link> (<xref ref-type="bibr" rid="bib28">Schoenfeld, 1983</xref>).</p></list-item></list></list-item></list><table-wrap id="tbl15" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Experiment duration</th><th>A priori power</th><th>Total events needed</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>(+)-JQ1</td><td>Vehicle</td><td>40 days</td><td>80%</td><td>4<xref ref-type="table-fn" rid="tblfn17">*</xref></td><td>5<xref ref-type="table-fn" rid="tblfn17">*</xref></td><td>5<xref ref-type="table-fn" rid="tblfn17">*</xref></td></tr><tr><td>(+)-JQ1</td><td>(−)-JQ1</td><td>40 days</td><td>80%</td><td>4<xref ref-type="table-fn" rid="tblfn17">*</xref></td><td>5<xref ref-type="table-fn" rid="tblfn17">*</xref></td><td>5<xref ref-type="table-fn" rid="tblfn17">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn17"><label>*</label><p>7 per group will be used based on the bioluminescence analysis making the power 94%.</p></fn></table-wrap-foot></table-wrap></p></sec></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Dr Andrew Kung, for generously sharing critical information as well as reagents to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Tissue Culture Collection (ATCC), BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma–Aldrich and System Biosciences (SBI).</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>IK: This is a Science Exchange associated lab.</p></fn><fn fn-type="conflict" id="conf2"><p>RP:CB: EI, FT, JL, and NP: Employed by and hold shares in Science Exchange Inc.</p></fn><fn fn-type="conflict" id="conf3"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>IK, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>HYJ, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>KO, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><year>2011</year><article-title>The future of treatment for patients with relapsed/refractory multiple myeloma</article-title><source>Oncology</source><volume>25</volume><supplement>(Suppl 2)</supplement><fpage>2</fpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Alsina</surname><given-names>M</given-names></name><name><surname>Bensinger</surname><given-names>W</given-names></name><name><surname>Biermann</surname><given-names>JS</given-names></name><name><surname>Chanan-Khan</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>AD</given-names></name><name><surname>Devine</surname><given-names>S</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Faber</surname><given-names>EA</given-names><suffix>Jr</suffix></name><name><surname>Gasparetto</surname><given-names>C</given-names></name><name><surname>Huff</surname><given-names>CA</given-names></name><name><surname>Kassim</surname><given-names>A</given-names></name><name><surname>Medeiros</surname><given-names>BC</given-names></name><name><surname>Meredith</surname><given-names>R</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Schriber</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Somlo</surname><given-names>G</given-names></name><name><surname>Stockerl-Goldstein</surname><given-names>K</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Tricot</surname><given-names>G</given-names></name><name><surname>Weber</surname><given-names>DM</given-names></name><name><surname>Yahalom</surname><given-names>J</given-names></name><name><surname>Yunus</surname><given-names>F</given-names></name></person-group><year>2011</year><article-title>Multiple myeloma</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>9</volume><fpage>1146</fpage><lpage>1183</lpage></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Kuehl</surname><given-names>WM</given-names></name></person-group><year>2005</year><article-title>Molecular pathogenesis and a consequent classification of multiple myeloma</article-title><source>Journal of Clinical Oncology</source><volume>23</volume><fpage>6333</fpage><lpage>6338</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.021</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisgrove</surname><given-names>DA</given-names></name><name><surname>Mahmoudi</surname><given-names>T</given-names></name><name><surname>Henklein</surname><given-names>P</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>104</volume><fpage>13690</fpage><lpage>13695</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705053104</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chng</surname><given-names>WJ</given-names></name><name><surname>Huang</surname><given-names>GF</given-names></name><name><surname>Chung</surname><given-names>TH</given-names></name><name><surname>Ng</surname><given-names>SB</given-names></name><name><surname>Gonzalez-Paz</surname><given-names>N</given-names></name><name><surname>Troska-Price</surname><given-names>T</given-names></name><name><surname>Mulligan</surname><given-names>G</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name></person-group><year>2011</year><article-title>Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma</article-title><source>Leukemia</source><volume>25</volume><fpage>1026</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1038/leu.2011.53</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>BH</given-names></name></person-group><year>2002</year><article-title>Calculating a factorial ANOVA from means and standard deviations</article-title><source>Understanding Statistics</source><volume>1</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1207/S15328031US0103_04</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conacci-Sorrell</surname><given-names>M</given-names></name><name><surname>McFerrin</surname><given-names>L</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name></person-group><year>2014</year><article-title>An overview of MYC and its interactome</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>4</volume><fpage>a014357</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a014357</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><year>2002</year><article-title>Transcription factors as targets for cancer therapy</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>740</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/nrc906</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name></person-group><year>2011</year><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Karpova</surname><given-names>T</given-names></name><name><surname>McNally</surname><given-names>J</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year>2009</year><article-title>Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>4899</fpage><lpage>4909</lpage><pub-id pub-id-type="doi">10.1091/mbc.E09-05-0380</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felsher</surname><given-names>DW</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><year>1999</year><article-title>Reversible tumorigenesis by MYC in hematopoietic lineages</article-title><source>Molecular Cell</source><volume>4</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80367-6</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Picaud</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>WB</given-names></name><name><surname>Fedorov</surname><given-names>O</given-names></name><name><surname>Morse</surname><given-names>EM</given-names></name><name><surname>Keates</surname><given-names>T</given-names></name><name><surname>Hickman</surname><given-names>TT</given-names></name><name><surname>Felletar</surname><given-names>I</given-names></name><name><surname>Philpott</surname><given-names>M</given-names></name><name><surname>Munro</surname><given-names>S</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Christie</surname><given-names>AL</given-names></name><name><surname>West</surname><given-names>N</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Heightman</surname><given-names>TD</given-names></name><name><surname>La Thangue</surname><given-names>N</given-names></name><name><surname>French</surname><given-names>CA</given-names></name><name><surname>Wiest</surname><given-names>O</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><year>2010</year><article-title>Selective inhibition of BET bromodomains</article-title><source>Nature</source><volume>468</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1038/nature09504</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>I</given-names></name><name><surname>Murphy</surname><given-names>DJ</given-names></name><name><surname>Swigart</surname><given-names>LB</given-names></name><name><surname>Knies</surname><given-names>U</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><year>2004</year><article-title>Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia</article-title><source>Oncogene</source><volume>23</volume><fpage>5923</fpage><lpage>5930</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207796</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Felsher</surname><given-names>DW</given-names></name></person-group><year>2014</year><article-title>MYC activation is a hallmark of cancer initiation and maintenance</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>4</volume><fpage>a014241</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a014241</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne</surname><given-names>G</given-names></name><name><surname>Stewart</surname><given-names>H</given-names></name><name><surname>Dickson</surname><given-names>J</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>Ramsahoye</surname><given-names>B</given-names></name><name><surname>Chevassut</surname><given-names>T</given-names></name></person-group><year>2014</year><article-title>Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1</article-title><source>Stem Cells and Development</source><volume>24</volume><fpage>879</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1089/scd.2014.0302</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Lahuerta</surname><given-names>JJ</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Haessler</surname><given-names>J</given-names></name><name><surname>Feather</surname><given-names>J</given-names></name><name><surname>Hoering</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>LeLeu</surname><given-names>X</given-names></name><name><surname>Hulin</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>SK</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Blade</surname><given-names>J</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Miguel</surname><given-names>JS</given-names></name><name><surname>Orlowski</surname><given-names>R</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Sezer</surname><given-names>O</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Durie</surname><given-names>BG</given-names></name><collab>International Myeloma Working Group</collab></person-group><year>2012</year><article-title>Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study</article-title><source>Leukemia</source><volume>26</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1038/leu.2011.196</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakens</surname><given-names>D</given-names></name></person-group><year>2013</year><article-title>Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs</article-title><source>Frontiers in psychology</source><volume>4</volume><fpage>863</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2013.00863</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeRoy</surname><given-names>G</given-names></name><name><surname>Rickards</surname><given-names>B</given-names></name><name><surname>Flint</surname><given-names>SJ</given-names></name></person-group><year>2008</year><article-title>The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription</article-title><source>Molecular Cell</source><volume>30</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.01.018</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><year>2012</year><article-title>Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>19408</fpage><lpage>19413</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216363109</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loven</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>HA</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>2013</year><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title><source>Cell</source><volume>153</volume><fpage>320</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.036</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name></person-group><year>2014</year><article-title>Therapeutic strategies to inhibit MYC</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>4</volume><fpage>a014266</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a014266</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>JA</given-names></name><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sims</surname><given-names>RJ</given-names><suffix>III</suffix></name></person-group><year>2011</year><article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108190108</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name></person-group><year>2008</year><article-title>Reflecting on 25 years with MYC</article-title><source>Nature Reviews. Cancer</source><volume>8</volume><fpage>976</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/nrc2231</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>GJ</given-names></name><name><surname>Walker</surname><given-names>BA</given-names></name><name><surname>Davies</surname><given-names>FE</given-names></name></person-group><year>2012</year><article-title>The genetic architecture of multiple myeloma</article-title><source>Nature Reviews. Cancer</source><volume>12</volume><fpage>335</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1038/nrc3257</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicodeme</surname><given-names>E</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Schaefer</surname><given-names>U</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Chandwani</surname><given-names>R</given-names></name><name><surname>Marazzi</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Coste</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Kirilovsky</surname><given-names>J</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Lora</surname><given-names>JM</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Tarakhovsky</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Suppression of inflammation by a synthetic histone mimic</article-title><source>Nature</source><volume>468</volume><fpage>1119</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1038/nature09589</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>CJ</given-names></name><name><surname>Kopp</surname><given-names>N</given-names></name><name><surname>Bird</surname><given-names>L</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Bowman</surname><given-names>T</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name></person-group><year>2012</year><article-title>BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia</article-title><source>Blood</source><volume>120</volume><fpage>2843</fpage><lpage>2852</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-413021</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name></person-group><year>1983</year><article-title>Sample-size formula for the proportional-hazards regression model</article-title><source>Biometrics</source><volume>39</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.2307/2531021</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Kannan</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Stack</surname><given-names>BC</given-names><suffix>Jr</suffix></name><name><surname>Suen</surname><given-names>JY</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name></person-group><year>2014</year><article-title>BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo</article-title><source>Cancer Research</source><volume>74</volume><fpage>7090</fpage><lpage>7102</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0305</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Soucheray</surname><given-names>M</given-names></name><name><surname>Carretero</surname><given-names>J</given-names></name><name><surname>Kikuchi</surname><given-names>E</given-names></name><name><surname>Tchaicha</surname><given-names>JH</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>KA</given-names></name><name><surname>Cohoon</surname><given-names>TJ</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Akbay</surname><given-names>E</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name></person-group><year>2013</year><article-title>Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>6183</fpage><lpage>6192</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3904</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucek</surname><given-names>L</given-names></name><name><surname>Whitfield</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>CP</given-names></name><name><surname>Finch</surname><given-names>AJ</given-names></name><name><surname>Murphy</surname><given-names>DJ</given-names></name><name><surname>Sodir</surname><given-names>NM</given-names></name><name><surname>Karnezis</surname><given-names>AN</given-names></name><name><surname>Swigart</surname><given-names>LB</given-names></name><name><surname>Nasi</surname><given-names>S</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><year>2008</year><article-title>Modelling Myc inhibition as a cancer therapy</article-title><source>Nature</source><volume>455</volume><fpage>679</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1038/nature07260</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Team RC</collab></person-group><year>2014</year><article-title>R: a language and environment for statistical computing</article-title><comment>R Foundation for Statistical Computing. <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link></comment></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolani</surname><given-names>B</given-names></name><name><surname>Gopalakrishnan</surname><given-names>R</given-names></name><name><surname>Punj</surname><given-names>V</given-names></name><name><surname>Matta</surname><given-names>H</given-names></name><name><surname>Chaudhary</surname><given-names>PM</given-names></name></person-group><year>2014</year><article-title>Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors</article-title><source>Oncogene</source><volume>33</volume><fpage>2928</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.242</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trabucco</surname><given-names>SE</given-names></name><name><surname>Gerstein</surname><given-names>RM</given-names></name><name><surname>Evens</surname><given-names>AM</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Shultz</surname><given-names>LD</given-names></name><name><surname>Greiner</surname><given-names>DL</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year>2015</year><article-title>Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3346</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Chiang</surname><given-names>CM</given-names></name></person-group><year>2007</year><article-title>The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>13141</fpage><lpage>13145</lpage><pub-id pub-id-type="doi">10.1074/jbc.R700001200</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.07072.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Glass</surname><given-names>Christopher</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Diego</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Charles Sawyers (Senior editor), a Reviewing editor, and three reviewers.</p><p>The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.</p><p>This Registered Report submission proposes to replicate key findings in <xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>, which reported the ability of the BRD inhibitor JQ1 to suppress <italic>MYC</italic> expression in a myeloma cell line and to extend survival of mice transplanted with this cell line. There was general agreement among the three Referees that the proposed studies will assess the major findings of Delmore et al., and will be highly relevant. The referees made the following recommendations to improve the protocols.</p><p>Protocol 1:</p><p>One reviewer noted that one of the main strengths of the published study (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>) was that JQ1 treatment led to downregulation of Myc was not limited to MM1.S cells, and that the effect was observed in several MM cell lines (Figure 3H and 3I). This is a key observation and we recommend that the qPCR analyses be extended to the MM cell types indicated in Figures 2A and 3I.</p><p>Addition of one more time point is recommended, the 1h treatment with 500 nM (+)-JQ1. This will indicate whether the Myc downregulation by JQ1 is as dynamic as reported.</p><p>In addition to the qPCR primers for Myc and GAPDH mentioned, the exact qPCR primers used by (<xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref>) should be included.</p><p>One reviewer requested scripts and a detailed description of the calculation performed with R. For example in Protocol 1, in the subsection headed “Test family”, the following sentence can be added: F test statistic (interaction) has been calculated following <xref ref-type="bibr" rid="bib6">Cohen (2002)</xref> and the partial η2 has been calculated following <xref ref-type="bibr" rid="bib18">Lakens (2013)</xref>.</p><p>This reviewer disagrees with the choice of a simple two-way ANOVA. In the original paper (Figure 3B) paired Student's <italic>t</italic>-tests were used. Since the replicated experiments are similar to the original ones a repeated measures anova is more appropriate. A carefully chosen repeated measures ANOVA is a natural extension of the paired <italic>t</italic>-test and can simplify the implementation of the proposed meta-analysis. A drawback with a repeated measures ANOVA is that it can be more difficult to set the parameters to determine the power. In such a case a sensitivity analysis can be performed with the G* power software.</p><p>Protocol 2:</p><p>Weight of mice should be recorded at day-0/day of injection.</p><p>In this protocol the analyses following an ANOVA have been performed using Fisher's LSD correction and alpha error = 0.05. In its basic form (I think the one used in the protocol) the LSD correction is not taking into account that multiple comparisons will be performed and therefore a Bonferroni correction (or other corrections) must be employed. For Protocol 2 this brings alpha to 0.025 and in practice is not dramatically changing the power calculations. As an alternative to Fisher's LSD followed by Bonferroni, the Hayter-Fisher's LSD procedure (Hayter, 1986) controls the MFWER (maximum family wise error rate).</p><p>Fisher's LSD correction has been reported also for survival data but it doesn't apply to this kind of data. Also here we need a (Bonferroni) correction. For the survival data, power calculations were performed with the Sample Size Calculator, however I do not have a clear link to the software. The authors should provide all the used parameters and references.</p><p>References:</p><p>Anthony J. Hayter. The maximum familywise error rate of fisher's least significant difference test. Journal of the American Statistical Association, 81(396):1000–1004, 1986. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/01621459.1986.10478364">doi:10.1080/01621459.1986.10478364</ext-link></p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.07072.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Protocol 1</italic>:</p><p><italic>One reviewer noted that one of the main strengths of the published study (</italic><xref ref-type="bibr" rid="bib9"><italic>Delmore et al., 2011</italic></xref><italic>) was that JQ1 treatment led to downregulation of Myc was not limited to MM1.S cells, and that the effect was observed in several MM cell lines (Figure 3H and 3I). This is a key observation and we recommend that the qPCR analyses be extended to the MM cell types indicated in Figures 2A and 3I</italic>.</p><p>We agree that testing additional cell types (KMS11, OPM1, LR5, and INA6) provided additional evidence that the downregulation of Myc was not limited to MM1.S cells, however the Reproducibility Project: <italic>Cancer</italic> Biology aims to perform direct replications using the same methodology reported in the original paper. The additional cell types would be a conceptual replication, which we agree is a useful approach to test the experiment’s underlying hypothesis, but which is not an aim of the project. Aspects of an experiment not included in the original study are occasionally added to ensure the quality of the research, but by no means is a requirement of this project; rather, it is an extension of the original work. Adding additional aspects not included in the original study can be of scientific interest, and can be included if it is possible to balance them with the main aim of this project: to perform a direct replication of the original experiment(s). As such, we will restrict our analysis to the experiments being replicated and will not include discussion of experiments not being replicated in this study.</p><p><italic>Addition of one more time point is recommended, the 1h treatment with 500 nM (+)-JQ1. This will indicate whether the Myc downregulation by JQ1 is as dynamic as reported</italic>.</p><p>Thank you for the recommendation. We have updated the manuscript to reflect this additional time point.</p><p><italic>In addition to the qPCR primers for Myc and GAPDH mentioned, the exact qPCR primers used by (</italic><xref ref-type="bibr" rid="bib9"><italic>Delmore et al., 2011</italic></xref><italic>) should be included</italic>.</p><p>The qPCR primers included in this experimental design were reported in <xref ref-type="bibr" rid="bib9">Delmore et al., 2011</xref> (Supplemental information, Extended Materials and methods, Expression analysis).</p><p><italic>One reviewer requested scripts and a detailed description of the calculation performed with R. For example in Protocol 1, in the subsection headed “Test family”, the following sentence</italic> can <italic>be added: F test statistic (interaction) has been calculated following</italic> <xref ref-type="bibr" rid="bib6"><italic>Cohen (2002)</italic></xref> <italic>and the partial η2 has been calculated following</italic> <xref ref-type="bibr" rid="bib18"><italic>Lakens (2013)</italic></xref>.</p><p>Thank you for this recommendation. We have included a link to the scripts (<ext-link ext-link-type="uri" xlink:href="https://osf.io/bjrpc/?view_only=737ba0f51c474aa1bc2782a44fba34d5">https://osf.io/bjrpc/?view_only=737ba0f51c474aa1bc2782a44fba34d5</ext-link>). Additionally, we have added descriptions as suggested to more clearly describe the approach.</p><p><italic>This reviewer disagrees with the choice of a simple two-way ANOVA. In the original paper (Figure 3B) paired Student's</italic> t<italic>-tests were used. Since the replicated experiments are similar to the original ones a repeated measures ANOVA is more appropriate. A carefully chosen repeated measures ANOVA is a natural extension of the paired</italic> t<italic>-test and</italic> can <italic>simplify the implementation of the proposed meta-analysis. A drawback with a repeated measures ANOVA is that it</italic> can <italic>be more difficult to set the parameters to determine the power. In such a case a sensitivity analysis</italic> can <italic>be performed with the G* power software</italic>.</p><p>We thank the reviewer for catching the original analysis method. We have adjusted the planned analysis to include this approach. As the reviewer suggested, we conducted a sensitivity analysis for the repeated measures ANOVA using the planned sample size and assuming 0 correlation among repeat measures and a nonsphericity correction of 1 to allow for a conservative estimate. We included the two planned comparisons (paired <italic>t</italic>-tests) assuming a correlation between groups of 0. This is because we do not have access to the original raw data. Additionally, it is not clear what df was used in the original paper since the reported p values suggest a larger effect size estimate than using the estimated means and standard deviations reported in the figure. This is likely due to the combination of the technical replicates (3) being combined with the biological replicates (2) giving a df of 5, opposed to using only the biological replicates (what is proposed in this manuscript), which gives a df of 2. Thus, we used the point estimated from G*Power using the estimated values from the graph reported in Figure 3B.</p><p>We are also proposing to analyze the data as originally planned (as a between subjects design) since the experimental set-up suggests this analysis. The sample comes from multiple random dishes of cells treated with or without drug. As such, it is possible to have a different number of data points in one group (vehicle) than the other (JQ1), thus making matched samples difficult. We think it is reasonable to use the independent test, and both analysis designs are reported in the literature. This will be considered additional exploratory analysis since it was not originally reported.</p><p><italic>Protocol 2</italic>:</p><p><italic>Weight of mice should be recorded at day-0/day of injection</italic>.</p><p>This is a parameter we have in the manuscript. Protocol 2, Step 5b. Weight of mice will be recorded during each day of injection during the course of the experiment.</p><p><italic>In this protocol the analyses following an ANOVA have been performed using Fisher's LSD correction and alpha error = 0.05. In its basic form (I think the one used in the protocol) the LSD correction is not taking into account that multiple comparisons will be performed and therefore a Bonferroni correction (or other corrections) must be employed. For Protocol 2 this brings alpha to 0.025 and in practice is not dramatically changing the power calculations. As an alternative to Fisher's LSD followed by Bonferroni, the Hayter-Fisher's LSD procedure (Hayter, 1986) controls the MFWER (maximum family wise error rate)</italic>.</p><p>We agree with the reviewers comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter are ways to control for the MFWER, however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 2004 (Chapter 5) and Cohen, 2001 (Chapter 12).</p><p><italic>Fisher's LSD correction has been reported also for survival data but it doesn't apply to this kind of data. Also here we need a (Bonferroni) correction. For the survival data, power calculations were performed with the Sample Size Calculator, however I do not have a clear link to the software. The authors should provide all the used parameters and references</italic>.</p><p>Thank you for this correction. We have updated the power calculations to reflect this adjustment. The link to the online calculator used is included as a hyperlink in the manuscript and should direct you to here: <ext-link ext-link-type="uri" xlink:href="http://www.sample-size.net/sample-size-survival-analysis/">http://www.sample-size.net/sample-size-survival-analysis/</ext-link>, which includes the reference (<xref ref-type="bibr" rid="bib28">Schoenfeld, 1983</xref>) for the formulas used.</p><p>Additionally, screen shots of the input and output parameters are included on the project page on the Open Science Framework.</p><p><italic><underline>References</underline></italic><underline>:</underline></p><p>Levin, J.R., Serline, R.C., &amp; Seaman M.A. (1994). A controlled, powerful multiple-comparison strategy for several situations. Psychological Bulletin, 115, 153–159.</p><p>Maxwell, S.E. &amp; Delaney, H.D. (2004). Designing experiments and analyzing data: a model comparison perspecitive. Lawrence Erlbaum Associates, Mahwah, N.J., second edition.</p><p>Cohen, B.H. (2001). Explaining psychological statistics. John Wiley and Sons, New York, second edition.</p></body></sub-article></article>